Egetis Therapeutics is a Swedish pharmaceutical company based in Stockholm, specializing in the late-stage development and commercialization of innovative treatments for serious rare diseases.

We focus on addressing significant unmet medical needs within the orphan drug segment, developing therapies like Emcitate® for MCT8 deficiency and Aladote® for paracetamol overdose.

Egetis distinguishes itself through its integrated approach to drug development, combining scientific expertise with a commitment to patient access. Our dedication to bringing life-changing medicines to patients with rare conditions drives our strategic focus and operational excellence.

Founded with a vision to transform patient outcomes, Egetis Therapeutics continues to expand its pipeline and global reach, solidifying its position as a key player in the pharmaceutical industry.

Emcitate® | Egetis Therapeutics

Product description

Egetis Therapeutics Stockholm, Sweden

Price: N/A

Egetis Therapeutics
Stockholm, Sweden